volume 277, issue 1-2, P73-79 2004
DOI: 10.1016/j.ijpharm.2003.03.003
View full text
|
|
Share

Abstract: The role of the newly discovered cysteine protease, cathepsin K, in osteoporosis and rheumatoid arthritis is reviewed. The current development of cathepsin K inhibitors and their targeted delivery using synthetic polymer carriers are discussed. Future challenges and possible strategies to improve these delivery systems are addressed.